CAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company has temporarily paused patient dosing and screening for its MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nex-z for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN), respectively. This ...

CELEBRATION, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it will report corporate and financial results for the third quarter 2025 on Wednesday, November 5, 2025, via a news release after the market close, and will host a conference call/audio webcast at 4:30 p.m. ET that day. A link to the audio webcast will ...

MELVILLE, N.Y., Oct. 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announced a major intellectual property milestone: the Japanese Patent Office has issued a Notice of Allowance for the Company’s ThermoStem® platform. The newly allowed patent provides broad protection for BioRestorative’s allogeneic, off-the-shelf brown ...

SEOUL, South Korea, Oct. 27, 2025 (GLOBE NEWSWIRE) -- MicrobiotiX Co., Ltd. (CEO Dongeun Yong), a company specializing in the development of novel bacteriophage therapeutics, announced on October 27 that it received Investigational New Drug (IND) approval from the Ministry of Food and Drug Safety (MFDS) on October 21 for MP101, its investigational bacteriophage therapy for patients with acute pneumonia. With this approval, MicrobiotiX becomes the first company in Korea to initiate ...

LOS ANGELES, Oct. 27, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against Baxter International Inc. (“Baxter” or “the Company”) (NYSE: BAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of BAX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff ...

ROBESONIA, Pa., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Blaqclouds, Inc. (OTC: BCDS), a leading Web3 infrastructure and decentralized finance company, today announced it has entered into a Blockchain & Development Partnership Agreement with Super Studios USA, an emerging powerhouse in film, television, and mixed-use real estate development. Under the terms of the agreement, Super Studios USA has funded the hard costs associated with the blockchain development of their project and ...

OTTAWA, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Telesat (Nasdaq and TSX: TSAT), one of the world’s largest and most innovative satellite operators, has scheduled a conference call on Tuesday, November 4, 2025, at 10:30 a.m. EST to discuss its financial results for the three and nine month periods ended September 30, 2025. Prior to the commencement of the call, Telesat will post a news release containing its financial results on its website (www.telesat.com) under the tab “Investors” and ...

Recent agreements with two additional U.S. mental health providers bring total to four in 2025 Strategy seeks to drive long-term shareholder value BURLINGTON, Mass. and JERUSALEM, Oct. 27, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced it has entered into two additional minority stake strategic investments, including an ...

CORNELIUS, N.C., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Alpha Modus Holdings, Inc. (NASDAQ: AMOD) today announced the appointment of Puneet “Pete” Vij as Vice President of Technology, where he will oversee the company’s national rollout of AlphaCash, its proprietary network of next-generation financial service kiosks. The rollout will be managed under Alpha Modus Financial Services, a newly formed subsidiary of Alpha Modus Holdings dedicated to advancing financial inclusion through ...

LOS ANGELES, Oct. 27, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against LifeMD, Inc. (“LifeMD” or “the Company”) (NASDAQ: LFMD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of LFMD during the class period listed are encouraged to contact the firm regarding possible lead plaintiff ...

SINGAPORE, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Sound Group Inc. (“Sound Group” or the “Company”) (NASDAQ: SOGP), a global AI-powered audio company, today announced that one of its subsidiaries has officially donated to establish the "HKUST(GZ) Information Hub - LIZHI Innovation Talent Scholarship" (the "LIZHI Innovation Talent Scholarship") at The Hong Kong University of Science and Technology (Guangzhou). The scholarship will provide recipients with opportunities to participate in ...

SAN DIEGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Netflix, Inc. (NASDAQ: NFLX). If you have information that could assist in the Netflix investigation or if you are a Netflix investor who suffered a loss and would like to learn more, you can provide your information here: You can also ...

ANN ARBOR, Mich., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, today announced the promotion of Dr. Xiaoli Zhang to the position of Chief Scientist. This promotion follows a series of groundbreaking scientific achievements under Dr. Zhang's leadership that are laying the foundation for the next generation of spider silk-based super materials. Dr. Zhang joined Kraig Labs in ...

- Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009 - WALTHAM, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced ...

LAS VEGAS, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Arcadia® (arcadia.io), a leading healthcare data platform, today announced the successful conclusion of Aggregate 2025, its annual customer conference. With 200+ attendees representing more than 50 organizations and a dozen partners, the three-day event featured intensive training, workflow consulting, peer knowledge exchange, real-world examples of innovation in action, and an immersive AI Showcase demonstrating how data and artificial ...

PORT ANGELES, Wash., Oct. 27, 2025 (GLOBE NEWSWIRE) -- First Northwest Bancorp (Nasdaq: FNWB) ("First Northwest" or the "Company"), the holding company for First Fed Bank ("First Fed" or the "Bank"), today reported net income of $802,000 for the third quarter of 2025, compared to net income of $3.7 million for the second quarter of 2025 and a net loss of $2.0 million for the third quarter of 2024. Basic and diluted income per share were $0.09 for the third quarter of 2025, compared ...

SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines in oncology and autoimmune disease, today announced the closing of its previously announced underwritten registered offering of 24,485,799 shares of its common stock at a purchase price of $10.21 per share. The gross proceeds to Nurix from the ...

Tonmya demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT studyTreatment was well tolerated with minimal effects on weight or blood pressure and discontinuation rate of 19% vs. placebo of 20.8% Data support the potential of Tonmya as a well-tolerated, centrally acting, non-opioid analgesic and therapeutic option for adults with fibromyalgia CHATHAM, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp.

- All primary and secondary interim analysis endpoints in FORTIFY Phase 3 study successfully achieved with well-tolerated safety profile consistent with the Company’s prior studies - Primary interim analysis endpoint, glycosylated αDG, significantly increased by 1.8x change from baseline at 3 months (p<0.0001), and improvements were sustained at 12 months (p<0.0001) in BBP-418 treated individuals versus placebo - Average reduction in serum CK, a marker of muscle damage, of ...

Data from the Phase 1 CARLYSLE study in severe refractory systemic lupus erythematosus (srSLE) suggests obe-cel is well tolerated with no ICANS or high-grade CRS; 50 million cell dose selected for Phase 2 pivotal studyPreliminary efficacy data demonstrate achievement of definition of remission in SLE (DORIS) in 83% of patients and complete renal response (CRR) in 50% of patients; all responses and remissions are ongoing with no evidence of disease activity at a median follow-up of ...